![]() |
|
|
Vol. 31, Issue 3, 319-325, March 2003
Département de Pharmacie Clinique (F.I., M.J., C.F., F.G.)
and Département de Parasitologie (J.C.G.), Faculté de
Pharmacie, Châtenay-Malabry, France; Hôpital Necker Enfants
Malades, Pharmacie, Paris, France (M.J., E.S., F.G.); Unité de
Mycologie Moléculaire, Institut Pasteur, Paris, France (F.D.);
Département d'Epidémiologie, de Biostatistique et de
Recherche Clinique, Hôpital Bichat Claude Bernard Unité
Inserm, Paris, France (G.B., F.M.); and Department of Preclinical
Pharmacokinetics, Johnson & Johnson Pharmaceutical Research and
Development, a division of Janssen Pharmaceutica N.V., Beerse, Belgium
(L.v.B.)
Itraconazole is a fungistatic agent that, although highly
lipophilic, shows poor transport through the blood brain barrier that
may be due to efflux proteins. The combined administration of an efflux
inhibitor with itraconazole should increase cerebral itraconazole
concentrations and therefore, improve the treatment of
Cryptococcus neoformans meningitis with this antifungal
agent. To test this hypothesis, we have studied the influence of murine cerebral infection with C. neoformans and the inhibition
of efflux by intraperitoneal injection of a P-glycoprotein inhibitor,
GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)-ethyl]-phenyl)9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide], on the pharmacokinetics of itraconazole in plasma and
brain after a single intraperitoneal itraconazole injection. We also
investigated the influence of efflux inhibition on the efficacy of
repeated doses of itraconazole in this murine model. The results showed
that in healthy and infected mice pretreated or not with GF120918,
plasma itraconazole values of area under the curve (AUC) were similar.
In contrast, cerebral values of AUC were higher in infected mice
compared with healthy mice. Moreover, the pretreatment of infected mice
with GF120918 significantly increased cerebral itraconazole values of
area under the curve and decreased weight loss in the treatment with
itraconazole of a cerebral infection with C. neoformans.
This article has been cited by other articles:
![]() |
C. E. Garner, E. Solon, C.-M. Lai, J. Lin, G. Luo, K. Jones, J. Duan, C. P. Decicco, T. Maduskuie, S. E. Mercer, et al. Role of P-Glycoprotein and the Intestine in the Excretion of DPC 333 [(2R)-2-{(3R)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl}-N-hydroxy-4-methylpentanamide] in Rodents Drug Metab. Dispos., June 1, 2008; 36(6): 1102 - 1110. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Meletiadis, S. Chanock, and T. J. Walsh Human Pharmacogenomic Variations and Their Implications for Antifungal Efficacy Clin. Microbiol. Rev., October 1, 2006; 19(4): 763 - 787. [Abstract] [Full Text] [PDF] |
||||